PARP-1 Deficiency Increases the Severity of Disease in a Mouse Model of Multiple Sclerosis*

  1. Wenbin Deng§,1
  1. From the Departments of Cell Biology and Human Anatomy and
  2. Neurology, School of Medicine, University of California, Davis, Sacramento, California 95817 and
  3. §Shriners Hospitals for Children, Sacramento, California 95817
  1. 1 To whom correspondence should be addressed: 2425 Stockton Blvd., Sacramento, CA 95817. Fax: 916-453-2288; E-mail: wbdeng{at}ucdavis.edu.

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) has been implicated in the pathogenesis of several central nervous system (CNS) disorders. However, the role of PARP-1 in autoimmune CNS injury remains poorly understood. Therefore, we studied experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis in mice with a targeted deletion of PARP-1. We identified inherent physiological abnormalities in the circulating and splenic immune composition between PARP-1−/− and wild type (WT) mice. Upon EAE induction, PARP-1−/− mice had an earlier onset and developed a more severe EAE compared with WT cohorts. Splenic response was significantly higher in PARP-1−/− mice largely because of B cell expansion. Although formation of Th1 and Th17 effector T lymphocytes was unaffected, PARP-1−/− mice had significantly earlier CD4+ T lymphocyte and macrophage infiltration into the CNS during EAE. However, we did not detect significant differences in cytokine profiles between PARP-1−/− and WT spinal cords at the peak of EAE. Expression analysis of different PARP isozymes in EAE spinal cords showed that PARP-1 was down-regulated in WT mice and that PARP-3 but not PARP-2 was dramatically up-regulated in both PARP-1−/− and WT mice, suggesting that these PARP isozymes could have distinct roles in different CNS pathologies. Together, our results indicate that PARP-1 plays an important role in regulating the physiological immune composition and in immune modulation during EAE; our finding identifies a new aspect of immune regulation by PARPs in autoimmune CNS pathology.

Footnotes

  • * This work was supported, in whole or in part, by National Institutes of Health Grants RO1 NS059043 and RO1 ES015988 (to W. D.) and RO1 NS025044 (to D. P. and A. S.). This work was also supported by grants from the National Multiple Sclerosis Society (to W. D.) and Shriners Hospitals for Children (to W. D.) and a postdoctoral fellowship from the California Institute for Regenerative Medicine (to M. M. S.).

  • Graphic The on-line version of this article (available at http://www.jbc.org) contains supplemental Table 1.

  • Received April 26, 2009.
  • Revision received June 26, 2009.
Table of Contents

Submit your work to JBC.

You'll be in good company.